ライフサイエンスコーパス: Zeiss

1 planted with diffractive IOL Acri.Lisa 366D (Zeiss, Oberkochen, Germany).

2 A Zeiss-Humphrey/Welch Allyn FDT perimeter was used with t

3 We have implemented this assay method into a Zeiss uHTS system and screened compound libraries for he

4 , the custom algorithm's RNFL thickness, and Zeiss' RNFL thickness was 0.980, 0.929, and 0.946, respe

5 ess measures from the commercially available Zeiss SD-OCT machine were obtained.

6 Between Zeiss' RNFL and the custom algorithm's RNFL, and the stu

7 timate of visual field loss; P = 0.003; Carl Zeiss Meditec, Inc., Dublin, CA).

8 as of the Humphrey Field Analyzer 24-2 (Carl Zeiss Meditec, Inc., Dublin, CA) visual field and the ax

9 red using the modified MPD-Visucam 200 (Carl Zeiss Meditec) and the modified Heidelberg Retina Angiog

10 tatic perimetric fields (Humphrey 30-2; Carl Zeiss Meditec, Dublin, CA) were obtained annually for 4

11 opters measured with the IOLMaster 500 (Carl Zeiss Meditec AG) were included.

12 preoperatively using the IOLMaster 500 (Carl Zeiss Meditec, Dublin, CA) to calculate the Haigis-L and

13 either 360 degrees ALPI (Visulas 532s; Carl Zeiss Meditec, Jena, Germany) or medical therapy (Travop

14 iSD-OCT) assisted PPV using Rescan 700 (Carl Zeiss Meditech, Jena, Germany) with epiretinal membrane

15 ndard program 24-2; Humphrey model 750 [Carl Zeiss Meditec, Dublin, CA]) printouts.

16 ral field (Humphrey Field Analyzer 750; Carl Zeiss Meditec).

17 , Liege, Belgium) or AT Lisa tri 839MP (Carl Zeiss AG, Jena, Germany).

18 cal diffractive IOL (AT LISA tri 839MP, Carl Zeiss Meditech, Germany).

19 A2, Carl Zeiss Meditec Inc., Dublin, CA) was investigated.

20 ression by Guided Progression Analysis (Carl Zeiss Meditec) of serial RNFL thickness maps.

21 (Cirrus HD-OCT RPE Elevation Analysis; Carl Zeiss Meditec).

22 ith the Humphrey Visual Field Analyzer (Carl Zeiss Meditec, Dublin, CA) from 189 normal eyes and 156

23 program of the Humphrey Field Analyzer (Carl Zeiss Meditec, Dublin, CA) of 76 patients with open-angl

24 rd, 24-2 test, Humphrey Field Analyzer, Carl Zeiss Meditec, Dublin, CA) and confocal scanning laser t

25 after injury) (Humphrey Field Analyzer, Carl Zeiss Meditec, Dublin, CA, Swedish Interactive Threshold

26 A-fast (Humphrey Visual Field Analyzer, Carl Zeiss Meditec, Inc, Dublin, CA) demonstrated diffuse dep

27 over 3 months (Humphrey Field Analyzer, Carl Zeiss Meditec; SITA Standard, 24-2).

28 spot size III; Humphrey Field Analyzer; Carl Zeiss Meditec, Inc., Dublin, CA) and frequency domain op

29 al field test (Humphrey Field Analyzer; Carl Zeiss Meditec, Inc., Dublin, CA).

30 A software (Cirrus 5000 with AngioPlex; Carl Zeiss Meditec).

31 cipants underwent gonioscopy and ASOCT (Carl Zeiss Meditec, Dublin, CA).

32 nt optical coherence tomography (ASOCT, Carl Zeiss Meditec, Dublin, CA).

33 ometry (the IOLMaster optical biometer; Carl Zeiss Meditec).

34 corneal compensation (GDx VCC; both by Carl Zeiss Meditec, Dublin, CA), according to different level

35 coherence tomography; both produced by Carl Zeiss Meditec, Inc., Dublin, CA), and optic nerve head (

36 and healthy subjects using the Cirrus (Carl Zeiss Meditec Inc., Dublin, CA) and Spectralis (Heidelbe

37 O, n = 400) acquired with Zeiss Cirrus (Carl Zeiss Meditec, Dublin, CA) (n = 600) or Heidelberg Spect

38 RNFL) thickness, as measured by Cirrus (Carl Zeiss, Oberkochen, Germany) optic coherence tomography (

39 HD-OCT (Cirrus; Carl Zeiss Meditec, Dublin, CA) volume scans (512 x 128) were

40 Prototype SD-OCTA devices (Cirrus; Carl Zeiss Meditec, Inc, Dublin, California, USA) were used t

41 s: scanning laser polarimetry (GDx ECC; Carl Zeiss Meditec, Dublin, CA), confocal scanning laser opht

42 Humphrey Matrix FDT (Carl Zeiss Meditec, Inc, Dublin, CA) testing was performed wi

43 mpensation; Glaucoma Diagnostics (GDx), Carl Zeiss Meditec, Dublin, CA) nerve fiber indicator (NFI),

44 using the Humphrey Field Analyzer (HFA; Carl Zeiss Meditec, Dublin, CA) SITA Fast 24-2 protocol.

45 s using a Humphrey Field Analyzer (HFA; Carl Zeiss Meditec, Dublin, CA; 24-2 Swedish interactive thre

46 lity of the Humphrey visual field (HVF; Carl Zeiss Meditec, Dublin, CA) test in subjects with glaucom

47 y maps from Humphrey visual field (HVF; Carl Zeiss Meditec, Inc., Dublin, CA) testing, as well as FDO

48 y testing (Humphrey Visual Field [HVF]; Carl Zeiss Meditec, Dublin, CA) and scanning laser ophthalmos

49 ent using a Humphrey Field Analyzer II (Carl Zeiss Meditec, Inc., Dublin, CA).

50 ted into a commercial OCT unit (OCT II; Carl Zeiss Meditec, Inc., Dublin, CA) and tested on healthy s

51 aminations (Humphrey Field Analyzer II; Carl Zeiss Meditec, Inc., Dublin, CA) in visual field series

52 totype Zeiss 100 kHz SS-OCT instrument (Carl Zeiss Meditec Inc, Dublin, CA).

53 r depth was determined using IOLMaster (Carl Zeiss Meditec).

54 and 30 myopes, by using the IOLMaster (Carl Zeiss Meditec, Inc., Dublin, CA), while accommodative st

55 vature were measured with an IOLMaster (Carl Zeiss Meditec, Welwyn Garden City, U.K.) at age 15 years

56 ACD) were measured using the IOLMaster (Carl Zeiss Meditech AG, Jena, Germany).

57 rence interferometry device (IOLMaster; Carl Zeiss Meditec, Inc., Dublin, CA) and an immersion ultras

58 The Humphrey Matrix (Carl Zeiss Meditec, Dublin CA; Welch-Allyn, Skaneateles, NY)

59 19 studies, 3094 subjects), Cirrus OCT (Carl Zeiss Meditec Inc., Dublin, CA) (14 studies, 2164 subjec

60 eyes were imaged by the Cirrus HD-OCT (Carl Zeiss Meditec Inc., Dublin, CA) and had visual field tes

61 n was examined by anterior segment OCT (Carl Zeiss Meditec) and the scans were analyzed in 2 axes (18

62 ne (ERM) by Cirrus spectral-domain OCT (Carl Zeiss Meditec) within a 2-year period.

63 cular scanning using the Cirrus HD-OCT (Carl Zeiss Meditec, Dublin, CA) macula 200x200 acquisition pr

64 morphology was assessed by Stratus OCT (Carl Zeiss Meditec, Dublin, CA).

65 ipants underwent gonioscopy and AS-OCT (Carl Zeiss Meditec, Dublin, CA).

66 s with Cirrus high-definition (HD)-OCT (Carl Zeiss Meditec, Dublin, CA).

67 eyes were imaged by the Cirrus HD-OCT (Carl Zeiss Meditec, Dublin, CA; optic nerve head and macular

68 obtained annually with the Stratus OCT (Carl Zeiss Meditec, Inc., Dublin, CA) along with optic disc s

69 dB) were imaged with OCT (Stratus OCT, Carl Zeiss Meditec, Inc., Dublin, CA) and tested with SAP (Hu

70 ical coherence tomography (Visante OCT, Carl Zeiss Meditec, Jena, Germany).

71 im, Germany) and SD-OCT (Cirrus HD-OCT; Carl Zeiss Meditec AG, Dublin, CA) at approximately 4-month i

72 al coherence tomography (Cirrus HD-OCT; Carl Zeiss Meditec Inc, Dublin, CA).

73 t AS optical coherence tomography (OCT; Carl Zeiss Meditec, Dublin, CA).

74 esponding SD OCT images (Cirrus HD-OCT; Carl Zeiss Meditec, Dublin, California, USA) were included.

75 ermany), AngioPlex (Cirrus 5000 HD-OCT; Carl Zeiss Meditec, Inc, Dublin, California, USA), prototype

76 tical coherence tomography (Cirrus OCT; Carl Zeiss Meditec, Inc, Dublin, California, USA).

77 atus optical coherence tomography (OCT; Carl Zeiss Meditec, Inc., Dublin, CA) images were analyzed wi

78 512 x 128 scan protocol; Cirrus HD-OCT; Carl Zeiss Meditec, Inc., Dublin, CA) was obtained from healt

79 ectance, spectral-domain OCT, and OCTA (Carl Zeiss Meditec), were performed.

80 California, USA), prototype PlexElite (Carl Zeiss Meditec), RS-3000 Advance (Nidek, Gamagori, Japan)

81 Progression Analysis software for SAP (Carl Zeiss Meditec, Inc.) and by masked assessment of optic d

82 FDT 24-2 Humphrey Matrix and SAP SITA (Carl Zeiss Meditec, Inc., Dublin, CA).

83 teractive Thresholding Algorithm, SITA; Carl Zeiss Meditec, Inc.) within 3 months of each other.

84 rrus 5000 with Angioplex OCTA software (Carl Zeiss Meditec, Dublin, CA).

85 SAP visual fields (SITA-standard; Carl Zeiss Meditec, Inc., Dublin, CA) were obtained within 22

86 area under the curve (AUC) and STATPAC (Carl Zeiss Meditec, Inc., Dublin, CA) PSD were compared.

87 optical coherence tomography (Stratus, Carl Zeiss Meditech AG).

88 StratusOCT (Carl Zeiss Meditec, Inc., Dublin, CA) images were collected f

89 The raw exported StratusOCT (Carl Zeiss Meditec, Inc., Dublin, CA) scan data from 20 eyes

90 coherence tomography (OCT; StratusOCT; Carl Zeiss Meditec, Dublin, CA) and scanning laser ophthalmos

91 tical coherence tomography (StratusOCT; Carl Zeiss Meditec, Inc.).

92 using VisuMax(R) 500 kHz laser system (Carl Zeiss Meditec, Jena, Germany) and the second group inclu

93 24-2 Humphrey visual field (HVF) test (Carl Zeiss Meditec, Dublin, CA); and (2) glaucomatous damage

94 Siegfried Czapski, the developer of the Carl Zeiss corneal biomicroscope, the direct precursor of tod

95 AT LISA trifocal IOL (AT LISA tri839MP; Carl Zeiss Meditec, Jena, Germany) pre-enrollment.

96 canning laser polarimeter (the GDx VCC; Carl Zeiss Meditec, Inc., Dublin, CA) assessed by receiver op

97 able Corneal and Lens Compensator (VCC; Carl Zeiss Meditec, Inc., Dublin, CA), the Heidelberg Retina

98 nd scanning laser polarimetry (GDx-VCC; Carl Zeiss Meditec, Inc., Dublin, CA).

99 by scanning laser polarimetry (GDx VCC; Carl Zeiss Meditec, Inc., Dublin, CA).

100 with 5 or more prior Humphrey 24-2 VFs (Carl Zeiss Meditec, Inc, Dublin, CA).

101 We analyzed ASOCT images (Visante, Carl Zeiss Meditec, Dublin, CA) from all subjects using custo

102 m anterior segment OCT images (Visante; Carl Zeiss Meditec, Inc., Dublin, CA) at 1 (CBT1), 2 (CBT2) a

103 cheimpflug and ocular wavefront (WASCA, Carl Zeiss Meditec AG) measurements were performed at the 3-m

104 g the Guided Progression Analysis (GPA; Carl-Zeiss Meditec, Inc., Dublin, CA).

105 any), and the Stratus OCT (Stratus OCT; Carl-Zeiss Meditec, Inc.) within a 6-month period.

106 actometry (Topcon), Pentacam HR, IOL Master (Zeiss) axial length measurements and fundus optical cohe

107 images obtained with SD-OCT (Cirrus HD-OCT, Zeiss Meditec, Dublin, California, USA) with 5.1.1 anter

108 Images were captured on Bioptigen SD-OCT, Zeiss Cirrus HD-OCT, and Heidelberg Spectralis in 42 eye

109 imaging, as well as imaging with a prototype Zeiss 100 kHz SS-OCT instrument (Carl Zeiss Meditec Inc,

110 n a Humphrey Field Analyzer (HFA) 24-2 test (Zeiss Humphrey Systems, Dublin, CA), and on a custom fre

111 ore and MD were obtained from 24-2 VF tests (Zeiss-Humphrey Systems, Dublin, CA) at two visits approx

112 ere acquired from all participants using the Zeiss Cirrus 5000 with Angioplex OCTA software (Carl Zei

113 S (SD: +/-15.2 years, range 18-65) using the Zeiss Visante AS-OCT and Medmont M300 corneal topographe

114 obtained with the software packaged with the Zeiss laser-scanning microscope (LSM AIM, version 3.2).

115 This Zeiss invention lacked only the slit illumination of tod

116 nts and fundus optical coherence tomography (Zeiss).

117 All the specimens were examined under Zeiss confocal laser scanning microscopy.

118 Images were digitized using Zeiss Axiovision software and densitometrically analyzed

119 s measured around the optic nerve head using Zeiss Stratus optical coherence tomography and related t

120 Using 55 eyes with valid Zeiss RNFL measurements, Pearson's correlation coefficie

121 vein occlusion (RVO, n = 400) acquired with Zeiss Cirrus (Carl Zeiss Meditec, Dublin, CA) (n = 600)